Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $34.83 Consensus PT from Analysts

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) have received a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $30.6667.

A number of equities research analysts have recently issued reports on the company. Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, July 28th. Wedbush dropped their price target on shares of Monte Rosa Therapeutics from $37.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday. JPMorgan Chase & Co. lifted their price objective on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Zacks Research lowered shares of Monte Rosa Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Finally, Guggenheim raised their target price on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th.

Monte Rosa Therapeutics Stock Performance

NASDAQ:GLUE opened at $15.61 on Thursday. The stock’s 50-day simple moving average is $20.68 and its 200 day simple moving average is $19.43. The company has a market cap of $1.32 billion, a P/E ratio of -10.55 and a beta of 1.59. Monte Rosa Therapeutics has a 52-week low of $4.12 and a 52-week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The company had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. As a group, equities analysts predict that Monte Rosa Therapeutics will post -1.23 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Anthony M. Manning sold 10,000 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $23.11, for a total value of $231,100.00. Following the sale, the director owned 10,000 shares in the company, valued at approximately $231,100. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Filip Janku sold 5,407 shares of the firm’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $24.50, for a total value of $132,471.50. Following the sale, the insider directly owned 60,612 shares of the company’s stock, valued at $1,484,994. This represents a 8.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 81,778 shares of company stock worth $1,768,581 over the last ninety days. 6.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Large investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC lifted its holdings in shares of Monte Rosa Therapeutics by 16.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after buying an additional 451 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Monte Rosa Therapeutics by 32.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after acquiring an additional 776 shares in the last quarter. ProShare Advisors LLC grew its stake in shares of Monte Rosa Therapeutics by 11.8% in the fourth quarter. ProShare Advisors LLC now owns 11,374 shares of the company’s stock valued at $178,000 after acquiring an additional 1,199 shares in the last quarter. MetLife Investment Management LLC increased its position in Monte Rosa Therapeutics by 7.5% during the fourth quarter. MetLife Investment Management LLC now owns 26,187 shares of the company’s stock worth $411,000 after acquiring an additional 1,831 shares during the period. Finally, GAMMA Investing LLC bought a new position in Monte Rosa Therapeutics during the fourth quarter worth about $30,000. 79.96% of the stock is owned by institutional investors.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.